Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482247 · ClinicalTrials.gov registry record · Phase 2
L-Arginine, Vascular Response and Mechanisms
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01482247: Completed Phase 2 study, sponsored by Brigham and Women's Hospital.
NCT01482247 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01482247, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of the study is to employ the supplement L-arginine to test the hypothesis that activation of blood flow to the brain during cognitive tasks is regulated by nitric oxide in older subjects with diabetes mellitus and/or hypertension (high blood pressure).
Interventions
- DIETARY_SUPPLEMENT Placebo Supplement
- DIETARY_SUPPLEMENT L-Arginine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
What the finished NCT01482247 record still lists
NCT01482247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Supplement is the first listed.
NCT01482247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01482247 about?
NCT01482247 is a clinical study titled "L-Arginine, Vascular Response and Mechanisms". The purpose of the study is to employ the supplement L-arginine to test the hypothesis that activation of blood flow to the brain during cognitive tasks is regulated by nitric oxide in older subjects with diabetes mellitus and/or hypertension (high blood pressure).
What is the current status of trial NCT01482247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2012-04. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01482247?
The interventions under investigation include: Placebo Supplement (DIETARY_SUPPLEMENT), L-Arginine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01482247?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01482247's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia